



Pharma & Food Solutions

METHOCEL™ DC2 Premium Excipients

Saving the Industry Time and Money to Focus on
Life-saving Innovations



Formulate with Cost Efficiency in Mind

METHOCEL™ DC2 Premium Excipients help you enjoy the benefits of dry powder processing techniques while maintaining consistent modified release performance. They offer the performance reliability expected from the proven family of METHOCEL™ CR excipients.

METHOCEL™ DC2 polymers are designed to offer:

- Considerably improved flow properties, providing excellent processability in the industry-preferred methods of roller compaction and direct compression;
- Greater reproducibility in tablet properties, such as weight uniformity, hardness and content uniformity;
- Shortened development time and lower manufacturing costs (up to 60%) through the elimination of the wet granulation process;
- Convenience and Reliability, with low regulatory hurdles to use, as they are pure pharmacopeial HPMC;
- Better formulation option for heat- and moisture-sensitive APIs.

METHOCEL™ DC2 Advantages:

- Science-based, designed morphology, enabling the switch from batch wet granulation techniques to continuous dry processing techniques, like roller compaction and direct compression
- Pure pharmacopeial HPMC, no additives
- Demonstrated benefits using multiple model API Formulations
- Reliably supplied from Midland, Michigan, United States, with alternative production in Bomlitz, Germany



Considerably Improved Flow Properties


The powder bulk flow of METHOCEL™ DC2 is greatly improved over that of METHOCEL™ CR.

Differences in morphology drive the improved flow and processability.

METHOCEL™ DC2 has:

- Less fines;
- More spherical morphology.

Powder Bulk Flow Rate of METHOCEL™ DC2



It should be noted that METHOCEL™ DC2 is chemically identical to METHOCEL™ CR. Thus, METHOCEL™ DC2 meets all HPMC pharmacopeial requirements.

Morphology Grade Within Chemistry / MW Grade

Data is based on results from internal studies.

Funnel Flow Test

Screen shots of a time lapse video over 14 seconds show the difference in powder flow through a glass funnel between METHOCEL™ DC2 and METHOCEL™ CR.



Internal Test from DOW R&D, Midland, MI (2014)

Excellent Processability in Dry Powder Techniques, Such As Direct Compression and Roller Compaction


Streamline Manufacturing and Gain Efficiencies:

In the example table displayed below, a comparison between a wet granulation and direct compression process illustrates the potential for significant time and cost savings for tablet manufacturers.


| | Cost / hour | High Shear Wet Granulation | Direct Compression |
|------------------------|-------------|----------------------------|--------------------|
| | | Hours | Hours |
| Equipment Preparation | \$150 | 3 | 1 |
| Material Dispensing | \$120 | 3 | 3 |
| Excipient Blend | \$160 | 1 | 1 |
| Lubrication Blend | \$160 | 0.5 | 0.5 |
| High Shear Granulation | \$240 | 1 | 0 |
| Drying the Granulation | \$240 | 1 | 0 |
| Granulation Sizing | \$120 | 1 | 0 |
| Clean up Costs | \$120 | 5 | 1 |
| Total Hours | | 15.5 | 6.5 |
| Savings | | | ~61%* |

* Actual Results will vary based on formulation, manufacturing process and labor costs.


Direct Compression



Dry Granulation



Wet Granulation



Source: Chemical Engineering, November 2003


While METHOCEL™ CR is an excellent option in wet granulation, METHOCEL™ DC2 enables both direct compression and roller compaction.

Greater Reproducibility In Tablet Properties

Consistency


The figures below illustrate that METHOCEL™ DC2 facilitates higher reproducibility in weight and content uniformity when used for direct compression.

METHOCEL™ DC2 Control Chart: Tablet Weight



UCL = 213.31 CpK: 3.397
 Avg = 209.43 Sigma Level: 10 σ
 LCL = 205.55

METHOCEL™ CR Control Chart: Tablet Weight




UCL = 207 CpK: 1.594
 Avg = 198.73 Sigma Level: 4 σ
 LCL = 190.46

Results from internal studies carried out in 2013 using a gliclazide model formulation.

Uniformity


API content uniformity remained consistent with METHOCEL™ DC2, but showed signs of API segregation over the duration of the direct compression trial with METHOCEL™ CR.

METHOCEL™ DC2 Run Chart: API Content per Tablet



UCL = 109.09
 Avg = 99.61
 LCL = 90.13

METHOCEL™ CR Run Chart: API Content per Tablet



UCL = 116.77
 Avg = 104.69
 LCL = 92.61

Metformin HCl Formulation


Roller Compaction

The following charts show the results from an internal study of a metformin HCl formulation, produced using dry granulation/roller compaction. When using dry powder processing techniques, like Roller Compaction, formulators can achieve more reproducible tablet properties with METHOCEL™ DC2.


Tablet Weight

The tablets produced with METHOCEL™ DC2 showed less tablet-to-tablet weight variation. Both grades exhibited similar modified release performance, matching the control (commercially available tablet).

METHOCEL™ DC2




METHOCEL™ CR



Metformin Release Profiles


METHOCEL™ DC2 and CR grades deliver the expected modified release performance.



Tablet Assays – Roller Compacted Material

An assay of the tablets shows greater API content uniformity when using METHOCEL™ DC2.

- Assays measured on individual tablets
- % API based on expected content per tablet







CONTROLLED RELEASE ALLIANCE

Our Direct Compression Portfolio

Three direct compression grades are currently available: METHOCEL™ K100LV Premium DC2, METHOCEL™ K4M Premium DC2 and METHOCEL™ K100M Premium DC2. These polymers have been developed to optimize dry powder processability while maintaining the same viscosities, degrees of methyl and hydroxypropyl substitution, and other important properties as the corresponding Controlled Release (CR) grades. The DC2 grades are chemically identical to original METHOCEL™ Premium products. The DC2 grades meet US Pharmacopoeia, European Pharmacopoeia and Japanese Pharmacopoeia monograph.

Colorcon/Dow Controlled Release Alliance Support

- Dow polymer chemistry expertise and manufacturing capability
- Colorcon dedicated team provides formulation expertise
- Starter formulations available through Colorcon HyperStart formulation service
- Colorcon local technical support for trials, scale-up and troubleshooting
- Colorcon global supply and logistics

| | |
|-----------------------------|------------------|
| North America | +1 800 447 4369 |
| Europe, Middle East, Africa | +31 11 567 2626 |
| Pacific | +60 3 7965 5392 |
| Latin America | +55 11 5184 8722 |

www.dowpharmaandfood.com

®™ Trademark of The Dow Chemical Company ("Dow") or an affiliated company of Dow • Form No. 198-02295 0914 CDP

Dow requests that customers considering use of Dow products in medical applications notify Dow so that appropriate assessments may be conducted. Dow has a Corporate Medical Application Policy in place that guides the use of Dow products in potential new pharmaceutical and medical device uses. Dow reviews all new applications/uses according to this Medical Application Policy to determine if the use is appropriate for Dow materials. Dow does not endorse or claim suitability of its products for specific medical applications. It is the responsibility of the medical device or pharmaceutical manufacturer to determine that the Dow product is safe, lawful, and technically suitable for the intended use. DOW MAKES NO WARRANTIES, EXPRESS OR IMPLIED, CONCERNING THE SUITABILITY OF ANY DOW PRODUCT FOR USE IN MEDICAL APPLICATIONS.

NOTICE: No freedom from infringement of any patent owned by Dow or others is to be inferred. Because use conditions and applicable laws may differ from one location to another and may change with time, Customer is responsible for determining whether products and the information in this document are appropriate for Customer's use and for ensuring that Customer's workplace and disposal practices are in compliance with applicable laws and other government enactments. The product shown in this literature may not be available for sale and/or available in all geographies where Dow is represented. The claims made may not have been approved for use in all countries. Dow assumes no obligation or liability for the information in this document. References to "Dow" or the "Company" mean the Dow legal entity selling the products to Customer unless otherwise expressly noted. NO WARRANTIES ARE GIVEN; ALL IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE ARE EXPRESSLY EXCLUDED.